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To assess the progression of Stargardt (STGD) disease over nine years in two branches of a large consanguineous
Tunisian family. Initially, diﬀerent phenotypes were observed with clinical intra- and interfamilial variations. At
presentation, four diﬀerent retinal phenotypes were observed. In phenotype 1, bull’s eye maculopathy and slight
alteration of photopic responses in full-ﬁeld electroretinography were observed in the youngest child. In phenotype 2,
macular atrophy and yellow white were observed in two brothers. In phenotype 3, diﬀuse macular, peripapillary, and
peripheral RPE atrophy and hyperﬂuorescent dots were observed in two sisters. In phenotype 4, Stargardt disease-
fundus ﬂavimaculatus phenotype was observed in two cousins with later age of onset. After a progression of 9 years,
all seven patients displayed the same phenotype 3 with advanced stage STGD and diﬀuse atrophy. WES and MLPA
identiﬁed two ABCA4 mutations M1: c.[(?_4635)_(5714+?)dup; (?_6148)_(6479_+?) del] and M2: c.[2041C>T], p.[R681∗].
In one branch, the three aﬀected patients had M1/M1 causal mutations and in the other branch the two aﬀected
patients had M1/M2 causal mutations. After 9-year follow-up, all patients showed the same phenotypic evolution,
conﬁrming the progressive nature of the disease. Genetic variations in the two branches made no diﬀerence to similar
end-stage disease.
1. Introduction
The ATP-binding cassette transporter ABCA4, also known
as ABCR, is a member of the ATP-binding cassette trans-
porter gene subfamily A [1]. ABCA4 is found in the outer
segment disk membrane photoreceptor cells [2] and also
marginally present in the brain [3].
ABCA4 is important in the visual cycle, as a retinoid
transporter of the toxic all-trans retinal out of the disc for
recycling by the retinal pigment epithelium (RPE) [4].
Without this function, an accumulation of toxic all-trans-
retinal derivatives in rods and cones may cause an apoptosis
of the supporting retinal pigment epithelium cells and,
ultimately, degeneration of photoreceptors [5, 6].
Mutations in ABCA4 gene are known to cause Stargardt
disease (STGD) which is the most frequent macular dystro-
phy [7] and typically presents with central macular atrophy
and yellow-white dots at the posterior pole, primarily at the
level of the RPE. Additional diseases were also linked to
mutations in ABCA4 including fundus ﬂavimaculatus,
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cone-rod dystrophy (CRD), and retinitis pigmentosa [8–11]
or variants considered as a risk factor for age-related macular
degeneration [12, 13].
The present study reports the molecular origin and
clinical evolution in a large Tunisian family with remark-
able variations in STGD and CRD phenotypes. This
family was initially published in 2013 [14]. We now pres-
ent a 9-year follow-up, showing progressive disease in all
patients with evolution to a similar phenotype of diﬀuse
macular, peripapillary, and peripheral RPE atrophy and
hyperﬂuorescent dots.
2. Patients and Methods
2.1. Patients’ Recruitment. We followed a large multiplex
family originating from Southern Tunisia (Gafsa) whose
initial presentation was published previously [12]. Twelve
subjects from two branches (A and B) with autosomal reces-
sive STGD disease were enrolled between March 2005 and
January 2014. Written informed consent was obtained from
each study participant. Analyses were done in accordance
with local guidelines, and regulation study was approved by
the Local Ethics Committee of the Hedi Rais Institute.
In accordance with the Helsinki Declaration, clinical
examination was performed in 7 patients, biological material
was obtained from 11 members, and family genealogical data
were gathered (Figure 1).
2.2. Clinical Investigation. A detailed clinical examination
including visual acuity, fundus photography, ﬂuorescein
angiography, and electroretinography (full-ﬁeld ERG) were
performed for all subjects. The initial data were compared
to those at follow-up.
Patients were classiﬁed into four phenotypes:
(i) Phenotype 1: bull’s eye maculopathy, slightly altered
photopic responses on full-ﬁeld ERG
(ii) Phenotype 2: macular atrophy and yellow-white
dots, altered photopic responses on full-ﬁeld ERG
(iii) Phenotype 3: diﬀuse macular, peripapillary, and
peripheral RPE atrophy and hyperﬂuorescent dots,
altered photopic and scotopic responses on full-
ﬁeld ERG.
(iv) Phenotype 4: Stargardt disease-fundus ﬂavimacu-
latus (STGD-FFM) with central atrophy, yellow-
white dots, hyperﬂuorescent atrophic spots, and
silent choroid, altered photopic responses on full-
ﬁeld ERG (this phenotype appeared similar to phe-
notype II but was considered a separate nosology
due to older age of onset)
2.3. Molecular Analysis. Peripheral blood of all subjects was
collected for genomic DNA isolation from leukocytes using
the “salting out” standard method. A DNA sample of the
index patient was subjected to WES. WES was performed
using the Roche NimbleGen version 2 paired-end sample
preparation kit and Illumina HiSeq2000 at a mean coverage
×31. Sequence reads were aligned to the human genome
reference sequence (build hg19), and variants were identiﬁed
and annotated using the NextGene software package v.2.3.5.
(Softgenetics, State College, PA). To determine the regions of
homozygosity from the WES data, we used an in-house
developed Excel macro.
2.4. In Silico Analysis. All variants were ﬁrst ﬁltered against
several public databases for the minor allele frequency
(MAF)< 1%. dbSNP served as a reference to exclude any
known frequent variants. We only focused on nonsynon-
ymous variants, variants in splicing sites, and frame-shift
coding insertions or deletions. The pathogenicity index for
the identiﬁed missense mutations was calculated in silico
using Sorting Intolerant from Tolerant (SIFT) (http://sift.bii.
a-star.edu.sg/) and Polymorphism Phenotyping V2 (Poly-
Phen-2) (http://genetics.bwh.harvard.edu/pph2/). The Phy-
loP score and Grantham distances were also recorded to
check the nucleotide conservation and change in amino acid
physiochemical properties.
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Figure 1: Pedigree structure of the family and segregation analysis of ABCA4 mutations.
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2.5. Mutation Validation.Variants were conﬁrmed by Sanger
sequencing, and segregation analysis was done in the family.
The following primers designed to amplify exon 14 of
ABCA4 were used: ABCA4-14F: 5′-TCAACAAACATTTA
TTCTGCCTCT-3′ and ABCA4-14R: 5′-AGCTTCTCCAG
ATGGTCACG-3′. PCR was realized in a total reaction mix-
ture of 20μl, containing 20 ng of genomic DNA, 10 pmol
of each primer (Eurogentec, Liège, Belgium), and 10μl of
FastStart PCR Master Mix (Roche, Basel, Switzerland).
The DNA was denatured at 95°C for 1 minute, prior to
35 cycles of ampliﬁcation of 1min at 94°C, 1min at
58°C, 1min at 72°C, and the ﬁnal extension step at 72°C
for 10min using a GeneAmp 9700 thermal cycler (Applied
Biosystems, Carlsbad, California, USA). The ampliﬁed frag-
ment was sequenced using a BigDye terminator sequencing
kit (Perkin Elmer). Sequenced samples were puriﬁed using
Performa®V3 96-well short plate, according to manufac-
turer’s instructions, loaded in a 3100 XL ABI sequencer
(Applied Biosystems) and analyzed using ABI Prisms
Navigator Software.
2.6. MLPA. We performed multiplex ligation-dependent
probe ampliﬁcation (MLPA) on all family members to
conﬁrm a large deletion, suspected through lack of PCR
ampliﬁcation in cousins.
The following 2 kits were used: SALSA P151-B1 and
P152-B2 kits where both contained probes for all exons of
the ABCA4 gene. MLPA analysis was performed according
to manufacturer’s instructions (MRC, Holland, Amsterdam,
The Netherlands), and data analysis was carried out by
GeneMapper software. The MLPA test was performed twice
for conﬁrmation of abnormal changes.
3. Results
3.1. Clinical Data. At the 9-year follow-up control, all
7 patients displayed disease progression with advanced
stage STGD and diﬀuse RPE atrophy.
In branch A, 5 patients displayed STGD with initially 3
diﬀerent phenotypes [14]. Patient III7, who originally pre-
sented with phenotype 1, developed after 9 years a large
central area of pronounced chorioretinal atrophy in both
eyes, with yellow-white dots distributed at the posterior pole
and midperiphery. The peripapillary area was normal. Visual
acuity fell from 20/200 to 20/400. Full-ﬁeld ERG showed
both altered photopic and scotopic responses. Patients III3
and III6 with STGD-FFM phenotype 2, associating macular
atrophy, yellow-white dots, hyperﬂuorescent atrophic spots,
and silent choroid, developed diﬀuse macular, peripapillary,
and RPE atrophy extending beyond the vascular arcades.
The yellow-white dots in the midperiphery regressed to be
replaced by numerous atrophic dots. Full-ﬁeld ERG showed
both altered photopic and scotopic responses. Primary STGD
phenotype 3 III1 and III2 patients with diﬀuse macular, peri-
papillary, and peripheral RPE atrophy and hyperﬂuorescent
dots progressed to severe CRD, with extensive areas of atro-
phy, pigment clumping, and migration throughout the poste-
rior pole involving the peripheral retina. Hyperﬂuorescent
atrophic dots progressed with hypoﬂuorescent spots beyond
the vascular arcades.
In branch B, 2 patients III8 and III10 presented initial
phenotype 4 STGD (Stargardt fundus ﬂavimaculatus, later
age of onset) with central atrophy, yellow-white dots, macu-
lar atrophy, hyperﬂuorescent atrophic spots, and silent cho-
roid. After 9-year progression of the disease, both presented
CRD with diﬀuse macular, peripapillary, and peripheral
RPE atrophy, regression of the yellow-white dots, and
hyperﬂuorescent dots. Full-ﬁeld ERG showed severe altered
photopic and scotopic responses.
Phenotype progression of the disease is illustrated
in Figure 2.
Clinical results at baseline and follow-up are summarized
in Table 1.
3.2. Genetic Findings. Homozygosity mapping and Sanger
sequencing of retinal dystrophy-associated genes did not
reveal any mutation in this consanguineous family.
WES revealed a previously identiﬁed nonsense mutation
c.[2041C>T]; p.[R681∗] found in exon 14, but in heterozy-
gous form in the proband, which did not segregate with the
phenotype in the family. The aﬀected sister carried this
heterozygous mutation while the three aﬀected cousins were
wild type for this variant.
Multiplex ligation-dependent probe ampliﬁcation was
used to search for a potential deletion in the index
patient carrying the heterozygous nonsense mutation.
This analysis showed a new complex rearrangement in
ABCA4: a heterozygous deletion of exon 45 to 47 and
heterozygous duplication of exon 32 to 40. This rearrange-
ment was also observed in his sister. The index patient was
thus a compound heterozygous: c.[2041C>T], p.[R681∗];
c.[(?_-4635)_(5714+?)dup; (?_6148)_(6479_+?) del].
The three aﬀected cousins with no previously detected
mutation were then tested by MLPA, identifying the similar
complex rearrangement in a homozygous state.
4. Discussion
The aim of the current study was to provide a compre-
hensive genetic and clinical proﬁle of ABCA4-associated
diseases in a consanguineous Tunisian family. In the index
patient of branch A, we identiﬁed a new genomic rearrange-
ment c.[(?_-4635)_(5714+?)dup; (?_6148)_(6479_+?) del] in
ABCA4. This rearrangement was present in a homozygous
state in the two aﬀected brothers. To date, large genomic
rearrangements account for a minor portion of STGD disease
alleles. The ﬁrst one was described by Yatsenko et al. [15]. In
our cohort, this is the ﬁrst large genomic rearrangement
identiﬁed in Tunisian STGD patients.
It is likely that skipping of exons 45–47 and the
duplication of exons 32–40 aﬀect the three-dimensional
structure and thereby the function of the protein. Theo-
retically, these mutations could cause a shift in the read-
ing frame, resulting in a premature termination codon at
the NBD2 domain and the absence of C-terminal seg-
ment that is crucial for the proper folding of ABCA4 into
its native form. Alternatively, nonsense-mediated mRNA
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decay could inhibit protein production and generate a severe
loss of function. A malfunctioning ABCA4 cannot remove
N-retinylidene-phosphatidylethanolamine from photorecep-
tors. As a result, N-retinylidene-PE combines with another
substance to produce lipofuscin, which builds up in retinal
cells. The buildup of lipofuscin is toxic and causes progres-
sive vision loss in subjects with STGD macular degeneration.
However, in branch B of the family, the two cousins were
heterozygous for this large rearrangement and carry a
heterozygous nonsense mutation p.[R681∗]. This mutation
is localized in the transmembrane segment and was described
previously by two groups [16, 17]. More than 640 mutations
in ABCA4 have been found in diﬀerent forms of STGD. It is
unclear, however, how mutations in ABCA4 can cause diﬀer-
ent ocular disorders. A recent study evaluated the severity of
speciﬁc ABCA4 alleles and showed that variants localized in
the transmembrane segment must produce a suﬃcient
amount of functional ABCA4, but induce deterioration of
peripheral retinal function with time [18].
The identiﬁcation of these two new alleles c.[(?_4635)_
(5714+?)dup; (?_6148)_(6479_+?) del] and c.[2041C>T],
[(?_4635)_(5714+?)dup; (?_6148)_(6479_+?) del] in a
Tunisian family conﬁrms the potential complex variations
in ABCA4. The segregation analysis was important to con-
ﬁrm the molecular diagnosis. Our analysis could explain
the clinical data with diﬀerent phenotypes and age of onset
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Figure 2: (a, b) Primary phenotype. (c, d) Final phenotype after 9-year progression of the disease.
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[14]. Regarding phenotype and severity of visual symptoms,
the family showed Stargardt disease at various stages of pro-
gression. After a 9-year follow-up, all patients conﬁrmed the
progressive nature of the disease. Progressive retinal degener-
ation, including development/resorption of ﬂecks, atrophy
enlargement, and deterioration of retinal function, has been
reported in STGD [19, 20].
In patient III7 who initially presented phenotype 1, the
loss of visual acuity was accompanied by appearance of
yellow-white lesions at the level of RPE, which are referred
to as fundus ﬂecks. In full-ﬁeld ERG, we also found a progres-
sion to scotopic and photopic response alterations. Patients
with phenotypes 2 and 3 demonstrated atrophic-appearing
lesions within the macula and peripheral retina as previously
reported with a ﬁnal severe CRD phenotype as shown in
full-ﬁeld ERG responses [19]. Patients from branch B with
primary phenotype STGD-FFM characterized by a later
age of onset and a better primary visual acuity progressed
also into severe phenotype 3 with severe macular and
peripheral atrophy.
In terms of retinal function, STGD has been classiﬁed
into three full-ﬁeld ERG groups: group I with normal rod
and cone responses; group II with relative loss of photopic
function; and group III with both altered photopic and
scotopic functions [11]. ERG ﬁndings in our two branches
with primary diﬀerent ERG responses from preserved
photoreceptor response to both photopic and scotopic
altered responses and a ﬁnal severely altered ERG responses
highlighted the assumption of diﬀerent stages of progression
course of the disease from macular dystrophy to CRD in
ABCA4 mutations.
It has been demonstrated that genetic variability inﬂu-
enced the primary severity of the condition and that age of
onset correlated with the amount of ABCR activity in photo-
receptors [21, 22]. In addition, it was recognized that STGD-
FFM had an older age of onset as observed in our patients
and had slower progression and thus better prognosis [23].
However, in our two STGD-FFM patients, progression was
towards severe diﬀuse macular, peripapillary, and peripheral
RPE atrophy and regression of the yellow-white dots joining
severe phenotype 3 shown in branch A, irrespective of the
haplotype variability. This would suggest that the primary
phenotype observed corresponds to a stage of progression
of the disease in both branches and that genotypic diﬀerence
between M1/M1 versus M1/M2 will inﬂuence age of onset,
degree of progression, and rapidity of development of the
ﬁnal phenotype less severe in branch B.
In conclusion, the observed progression of disease
supports the hypothesis that all phenotypes described at an
initial stage of disease are variable stages of a single progres-
sive disease, depending on age in family A and on various
haplotype combinations in family B.
We report two genetically diﬀerent abnormalities in a
STGD consanguineous family. The mechanism by which
the large homozygous rearrangement, or the compound
heterozygous mutations, leads to the same phenotype after
9 years of follow-up is not fully understood. Further bio-
chemical and functional studies should provide deeper
insights into the pathogenesis of STGD.
Conflicts of Interest
The authors declare no conﬂict of interest.
Authors’ Contributions
Daniel F. Schorderet and Imen Habibi identiﬁed the muta-
tion. Yousra Falfoul, Ahmed Chebil, Ahmed Turki, Asma
Hassairi, and Leila El Matri referred patients and clinical
data. Yousra Falfoul, Imen Habibi, and Daniel F. Schorderet
wrote the paper. Yousra Falfoul and Imen Habibi prepared
the ﬁgures. Daniel F. Schorderet and Leila El Matri designed
the experiments. All authors reviewed and approved the
manuscript. Yousra Falfoul and Imen Habibi contributed
equally in the paper.
Acknowledgments
The authors acknowledge all the participating family mem-
bers and are thankful for their cooperation in this study.
The authors thank the family members for their invaluable
participation and cooperation. The authors acknowledge
the help provided by colleagues who referred patients to
them. The authors also thank Susan E. Houghton for editing
the manuscript. This work was supported by the Institute for
Research in Ophthalmology (IRO).
References
[1] M. Illing, L. L. Molday, and R. S. Molday, “The 220-kDa rim
protein of retinal rod outer segments is a member of the
ABC transporter superfamily,” Journal of Biological Chemistry,
vol. 272, no. 15, pp. 10303–10310, 1997.
[2] M. Dean and T. Annilo, “Evolution of the ATP-binding cas-
sette (ABC) transporter superfamily in vertebrates,” Annual
Review of Genomics and Human Genetics, vol. 6, no. 1,
pp. 123–142, 2005.
[3] J. Bhongsatiern, S. Ohtsuki, M. Tachikawa, S. Hori, and
T. Terasaki, “Retinal-speciﬁc ATP-binding cassette trans-
porter (ABCR/ABCA4) is expressed at the choroid plexus
in rat brain,” Journal of Neurochemistry, vol. 92, no. 5,
pp. 1277–1280, 2005.
[4] R. Allikmets, N. Singh, H. Sun et al., “A photoreceptor cell-
speciﬁc ATP-binding transporter gene (ABCR) is mutated in
recessive Starqardt macular dystrophy,” Nature Genetics,
vol. 15, no. 3, pp. 236–246, 1997.
[5] J. Weng, N. L. Mata, S. M. Azarian, R. T. Tzekov, D. G. Birch,
and G. H. Travis, “Insights into the function of Rim protein in
photoreceptors and etiology of Stargardt’s disease from the
phenotype in abcr knockout mice,” Cell, vol. 98, no. 1,
pp. 13–23, 1999.
[6] N. L. Mata, J. Weng, and G. H. Travis, “Biosynthesis of a major
lipofuscin ﬂuorophore in mice and humans with ABCR-
mediated retinal and macular degeneration,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 97, no. 13, pp. 7154–7159, 2000.
[7] B. Bocquet, A. Lacroux, M. O. Surget et al., “Relative frequen-
cies of inherited retinal dystrophies and optic neuropathies in
Southern France: assessment of 21-year data management,”
Ophthalmic Epidemiology, vol. 20, no. 1, pp. 13–25, 2013.
6 Journal of Ophthalmology
[8] A. Maugeri, B. J. Klevering, K. Rohrschneider et al.,
“Mutations in the ABCA4 (ABCR) gene are the major
cause of autosomal recessive cone-rod dystrophy,” The
American Journal of Human Genetics, vol. 67, no. 4,
pp. 960–966, 2000.
[9] M.Michaelides, A. J. Hardcastle, D. M. Hunt, and A. T. Moore,
“Progressive cone and cone-rod dystrophies: phenotypes and
underlying molecular genetic basis,” Survey of Ophthalmology,
vol. 51, no. 3, pp. 232–258, 2006.
[10] C. P. Hamel, “Cone rod dystrophies,” Orphanet Journal of
Rare Diseases, vol. 2, no. 1, p. 7, 2007.
[11] N. Lois, G. E. Holder, C. Bunce, F. W. Fitzke, and A. C. Bird,
“Phenotypic subtypes of stargardt macular dystrophy-fundus
ﬂavimaculatus,” Archives of Ophthalmology, vol. 119, no. 3,
pp. 359–369, 2001.
[12] R. Allikmets, N. F. Shroyer, N. Singh et al., “Mutation of the
Stargardt disease gene (ABCR) in age-related macular degener-
ation,” Science, vol. 277, no. 5333, pp. 1805–1807, 1997.
[13] R. Allikmets and International ABCR Screening Consortium,
“Further evidence for an association of ABCR alleles with
age-related macular degeneration,” The American Journal of
Human Genetics, vol. 67, no. 2, pp. 487–491, 2000.
[14] L. El Matri, F. Ouechtati, A. Chebil, L. Largueche, and
S. Abdelhak, “Clinical polymorphism of Stargardt disease in
a large consanguineous Tunisian family; implications for
nosology,” Journal of Ophthalmic & Vision Research, vol. 8,
no. 4, pp. 341–350, 2013.
[15] A. N. Yatsenko, N. F. Shroyer, R. A. Lewis, and J. R. Lupski,
“An ABCA4 genomic deletion in patients with Stargardt
disease,” Human Mutation, vol. 21, no. 6, pp. 636–644, 2003.
[16] A. Maugeri, M. A. Van Driel, D. J. R. van de Pol et al., “The
2588G→Cmutation in theABCR gene is a mild frequent foun-
der mutation in the Western European population and allows
the classiﬁcation of ABCRmutations in patients with Stargardt
disease,” American Journal of Human Genetics, vol. 64, no. 4,
pp. 1024–1035, 1999.
[17] M. Bertelsen, J. Zernant, M. Larsen, M. Duno, R. Allikmets,
and T. Rosenberg, “Generalized choriocapillaris dystrophy, a
distinct phenotype in the spectrum of ABCA4-associated
retinopathies,” Investigative Ophthalmology & Visual Science,
vol. 55, no. 4, pp. 2766–2776, 2014.
[18] A. Fakin, A. G. Robson, J. (P. W.) Chiang et al., “The eﬀect on
retinal structure and function of 15 speciﬁc ABCA4mutations:
a detailed examination of 82 hemizygous patients,” Investiga-
tive Ophthalmology & Visual Science, vol. 57, no. 14,
pp. 5963–5973, 2016.
[19] K. Fujinami, N. Lois, A. E. Davidson et al., “A longitudinal
study of Stargardt disease: clinical and electrophysiologic
assessment, progression, and genotype correlations,” Ameri-
can Journal of Ophthalmology, vol. 155, no. 6, pp. 1075–
1088.e13, 2013.
[20] R. A. Lewis, N. F. Shroyer, N. Singh et al., “Genotype/
phenotype analysis of a photoreceptor-speciﬁc ATP-binding
cassette transporter gene, ABCR, in Stargardt disease,” The
American Journal of Human Genetics, vol. 64, no. 2, pp. 422–
434, 1999.
[21] J. D. Armstrong, D. Meyer, S. Xu, and J. L. Elfervig, “Long-
term follow-up of Stargardt’s disease and fundus ﬂavimacula-
tus,” Ophthalmology, vol. 105, no. 3, pp. 448–457, 1998.
[22] K. Fuginami, N. Lois, R. Mukherjee et al., “A longitudinal
study of stargardt disease: quantitative assessment of fundus
autoﬂuorescence, progression, and genotype correlations,”
Investigative Ophthalmology & Visual Science, vol. 54, no. 13,
pp. 8181–8190, 2013.
[23] A. N. Yatsenko, N. F. Shroyer, R. Lewis, and J. Lupski,
“Late-onset Stargardt disease is associated with missense
mutations that map outside known functional regions of
ABCR (ABCA4),” Human Genetics, vol. 108, no. 4,
pp. 346–355, 2001.
7Journal of Ophthalmology
